You are here: Industry Insights > SCCHN

News List

FDA Approves New Dosing Regimen for Cetuximab americanpharmaceuticalreview
April 12, 2021
On April 6, 2021, the Food and Drug Administration approved a new dosage regimen of 500 mg/m2 as a 120-minute intravenous infusion every two weeks (Q2W) for cetuximab (Erbitux, ImClone LLC) for patients with K-Ras wild-type, EGFR-expressing colorectal ...
NICE no for BMS’ Opdivo for head and neck cancer pharmatimes
January 11, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has turned down Bristol Myers Squibb’s (BMS) immunotherapy Opdivo (nivolumab) for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum-based ...
NeoImmuneTech gets IND clearance for NT-I7 trial in locally recurrent SCCHN pharmaceutical-business-review
July 29, 2020
NeoImmuneTech announced receipt of IND clearance from the US Federal Drug Administration (FDA) to evaluate NT-I7 (efineptakin alfa), the only clinical-stage long-acting human IL-7, in a Window-of-Opportunity trial for patients with locally recurrent ...
Junshi Biosciences, Merck Partner on SCCHN Combo Therapy contractpharma
June 02, 2020
To study anti-PD-1 mAb toripalimab (TUOYI) in combination with Cetuximab (Erbitux) in metastatic squamous cell carcinomas of the head and neck in China.
Merck KGaA announces new results for bifunctional immunotherapy M7824 pharmatimes
October 25, 2018
Merck KGaA has announced new and updated results from expansion cohorts of two ongoing Phase I clinical trials (NCT02517398 and NCT02699515) for its immunotherapy M7824.